Sector
PharmaceuticalsOpen
₹1,550.1Prev. Close
₹1,539.15Turnover(Lac.)
₹10,583.23Day's High
₹1,559.9Day's Low
₹1,51152 Week's High
₹1,59252 Week's Low
₹834.65Book Value
₹342.22Face Value
₹1Mkt Cap (₹ Cr.)
89,537.28P/E
47.17EPS
32.62Divi. Yield
0.2930 Jul 2024
12:00 AM
BookCloser
30 Jul 2024
12:00 AM
AGM
Announcement Date: 30 Jul, 2024
10 Feb 2024
12:00 AM
Dividend
Dividend Amount: 1.5
Record Date: 20 Feb, 2024
31 Jul 2024
12:00 AM
Board Meeting
Agenda : Audited Result
The approval was based on a supplemental Abbreviated New Drug Application (sANDA) for an alternate facility for manufacturing and testing.
Aurobindo Pharma Ltd has gained a total of 79% in the last one year, and almost 45% since the beginning of the year.
Eugia Steriles, a 100% subsidiary of Eugia Pharma Specialities and a step down arm of Aurobindo Pharma, operates the new plant.
"Our China plant is expected to be commercialised in Q3 FY25, with a ramp-up beginning in Q4 FY25," Subramanian said during an analyst call.
An OAI status indicates that the USFDA's inspection discovered significant concerns that require regulatory or administrative action.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 58.59 | 58.59 | 58.59 | 58.59 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 19,664.23 | 17,975.44 | 17,058.75 | 15,866.02 |
Net Worth | 19,722.82 | 18,034.03 | 17,117.34 | 15,924.61 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 11,287.14 | 15,823.68 | 13,266.48 | 10,269.9 |
yoy growth (%) | -28.66 | 19.27 | 29.17 | 6.89 |
Raw materials | -5,846.25 | -7,244.82 | -6,523.53 | -4,562.81 |
As % of sales | 51.79 | 45.78 | 49.17 | 44.42 |
Employee costs | -1,600.04 | -1,735.42 | -1,561.47 | -1,131.64 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 1,712.19 | 4,193.01 | 2,377.7 | 2,342.94 |
Depreciation | -415.26 | -488 | -470.48 | -354.83 |
Tax paid | -182.77 | -1,080.1 | -504.96 | -530.17 |
Working capital | -1,929.49 | 771.58 | 1,700.35 | 1,554.63 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -28.66 | 19.27 | 29.17 | 6.89 |
Op profit growth | -64.23 | 53.39 | 0.58 | 12.47 |
EBIT growth | -59.04 | 61.21 | 9.29 | 7.73 |
Net profit growth | -53.26 | 66.22 | 3.3 | 6.21 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 28,704.5 | 24,617.13 | 23,366.55 | 24,557.95 | 22,737.95 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 28,704.5 | 24,617.13 | 23,366.55 | 24,557.95 | 22,737.95 |
Other Operating Income | 297.37 | 238.25 | 88.94 | 216.68 | 360.55 |
Other Income | 557.38 | 290.59 | 320.35 | 3,195.42 | 86.2 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,846.05 | 157.99 | 4,39,714.12 | 237.82 | 0.74 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,429.2 | 87.39 | 1,45,166.18 | 430 | 0.55 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,637.7 | 33.59 | 1,33,401.99 | 1,055.94 | 0.79 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,351.9 | 75.67 | 1,13,724.41 | 469 | 0.83 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,502.55 | 26.6 | 1,09,604.31 | 1,417.2 | 0.61 | 5,823.9 | 1,458.61 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Vice Chairman & M.D.
Kambam Nityananda Reddy
Whole-time Director
M Madan Mohan Reddy
Non Executive Director
P V Ramprasad Reddy
Independent Director
Savita Mahajan
Independent Director
Girish Paman Vanvari
Non Executive Director
P Sarath Chandra Reddy
Independent Director
Santanu Mukherjee
Independent Director
Deepali Pant Joshi
Chairman & Independent Directo
M R Kumar
Non Executive Director
Satakarni Makkapati
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Aurobindo Pharma Ltd
Summary
Aurobindo Pharma Limited (APL), one of the worlds top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company. Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it. APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations. The companys robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindos products. APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities. Aurobindo Pharma has identified international operations also catering to over 150 countries. The Company has accelerated the DMF/ANDA filings programme in its efforts to build a broad product portfolio for the regulated markets. Cumulatively, the Company has filed a total of 337 DMFs (Drug Master Files), of which 110 are with US FDA, and 133 in Europe including with the EDQM and 102 in other countries. This is one of the highest filings. The Company commenced its operations during the year 1988-89 with a single unit manufacturing semi synthetic penicillins (SS
Read More
What is the Aurobindo Pharma Ltd share price today?
The Aurobindo Pharma Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1528.1 today.
What is the Market Cap of Aurobindo Pharma Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Aurobindo Pharma Ltd is ₹89537.28 Cr. as of 19 Sep ‘24
What is the PE and PB ratio of Aurobindo Pharma Ltd?
The PE and PB ratios of Aurobindo Pharma Ltd is 47.17 and 4.57 as of 19 Sep ‘24
What is the 52 Week High and Low of Aurobindo Pharma Ltd?
The 52-week high/low is the highest and lowest price at which a Aurobindo Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Aurobindo Pharma Ltd is ₹834.65 and ₹1592 as of 19 Sep ‘24
What is the CAGR of Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd's CAGR for 5 Years at 19.99%, 3 Years at 29.28%, 1 Year at 72.05%, 6 Month at 51.25%, 3 Month at 23.86% and 1 Month at 1.31%.
What is the shareholding pattern of Aurobindo Pharma Ltd?
The shareholding pattern of Aurobindo Pharma Ltd is as follows:
Promoters - 51.80 %
Institutions - 41.50 %
Public - 6.70 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
